AI-Powered Liver Tumor Ablation Software Leverages CT, MRI and Ultrasound for Real-Time Image Guidance
Through the use of artificial intelligence (AI) and imaging modalities such as ultrasound, CT, and MRI, the newly FDA-cleared VisAble.IO software reportedly enhances planning and real-time assessment for liver tumor ablation procedures.
The Food and Drug Administration (FDA) has granted 510(k) clearance for VisAble.IO (TechsoMed), an artificial intelligence (AI)-enabled software that may facilitate improved real-time imaging guidance — through ultrasound and computed tomography (CT) or magnetic resonance imaging (MRI) — for liver tumor ablation procedures.
TechsoMed said the software’s advanced computation and image registration elevate the planning and real-time assessment of liver tumor ablation.
The company noted that key benefits of the VisAble.IO software include:
• three-dimensional (3D) anatomical views of ablation targets;
• overlay positioning of virtual instruments and ablation region estimates onto imaging; and
• immediate post-procedure 3D views to assess ablation margins and potentially missed volumes.
“There is a real need for a good and efficient assessment tool, and (VisAble.IO) can serve any physician performing thermal ablations,” noted Ryosuke Tateishi, M.D., Ph.D., an associate professor in the Department of Gastroenterology at the University of Tokyo.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
